Abstract

ObjectiveTo compare the long-term efficacy and safety of azathioprine (AZA), 18-month fixed-schedule rituximab (RTX), 18-month tailored RTX and 36-month RTX in preventing relapses in patients with antineutrophil cytoplasmic antibody (ANCA)-associated...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Ten-year experience with rituximab for induction and maintenance therapy in patients with ANCA-associated systemic vasculitis
E L Nasonov ... T V Beketova
Modern Rheumatology Journal | VOL. 14
E L Nasonov, et. al.E L Nasonov ... T V Beketova
22 Mar 2020
OP0213 Rituximab Versus Azathioprine for Maintenance in Antineutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis (MAINRITSAN): Follow Up at 34 Months
P Gobert ... T Quemeneur
Annals of the Rheumatic Diseases | VOL. 72
P Gobert, et. al.P Gobert ... T Quemeneur
01 Jun 2013
Maintenance Immunosuppression in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Michelle A Hladunewich ... Daniel C Cattran
American Journal of Kidney Diseases | VOL. 57
Michelle A Hladunewich, et. al.Michelle A Hladunewich ... Daniel C Cattran
19 Apr 2011
FRI0355 Comparison of Rituximab with Cyclophosphamide as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome): A 24 Months Follow-Up Analysis
K Halmschlag ... M Rizzi
Annals of the Rheumatic Diseases | VOL. 75
K Halmschlag, et. al.K Halmschlag ... M Rizzi
01 Jun 2016
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers